Dexpramipexole (KNS-760704)
Sponsors
Areteia Therapeutics Inc.
Conditions
Eosinophilic asthmaSevere Eosinophilic asthmaSevere eosinophilic asthma
Phase 3
A randomized, double-blind, placebo-controlled, parallel-group study to assess the efficacy, safety, and tolerability of dexpramipexole administered orally for 52 weeks in participants with severe eosinophilic asthma (EXHALE-3)
WithdrawnCTIS2023-503693-20-00
Target: 20Updated: 2023-09-12
A randomized, double-blind, placebo-controlled, parallel-group study to assess the efficacy, safety, and tolerability of dexpramipexole administered orally for 52 weeks in participants with severe eosinophilic asthma (EXHALE-3)
CompletedCTIS2023-503693-20-01
Start: 2024-04-10End: 2025-11-05Target: 490Updated: 2025-12-16
A randomized, double-blind, placebo-controlled, parallel-group study to assess the efficacy, safety, and tolerability of dexpramipexole administered orally for 24 weeks in participants with eosinophilic asthma (EXHALE-4)
CompletedCTIS2023-509739-22-00
Start: 2023-04-25End: 2025-07-18Target: 25Updated: 2025-07-14
An Open-Label Long-Term Phase III Extension Study to Assess the Long-Term Safety and Tolerability of Dexpramipexole in Participants with Severe Eosinophilic Asthma (EXHALE-5)
Not yet recruitingCTIS2024-510810-33-00
Start: 2024-10-14Target: 48Updated: 2025-11-03
A randomized, double-blind, placebo-controlled, parallel-group study to assess the efficacy, safety, and tolerability of dexpramipexole administered orally for 52 weeks in participants with severe eosinophilic asthma (EXHALE-2)
CompletedCTIS2023-507665-25-00
Start: 2023-04-25End: 2025-11-05Target: 430Updated: 2025-09-19